| Q89688806 | A Protein Epitope Targeted by the Antibody Response to Kawasaki Disease |
| Q37402867 | A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum |
| Q92396678 | A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults |
| Q47581449 | A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII. |
| Q90401221 | Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action |
| Q58086749 | Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children |
| Q91193628 | Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial |
| Q56357275 | CXCR3 T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria |
| Q90403559 | Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein |
| Q91883525 | Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers |
| Q90560580 | Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity |
| Q92022239 | Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination |
| Q64054854 | Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy |
| Q44168331 | Controlled Human Malaria Infection: Applications, Advances and Challenges. |
| Q57479092 | Cryo-EM structure of circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts |
| Q40096524 | Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis |
| Q57606160 | Disordered epitopes as peptide vaccines |
| Q92296514 | Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein |
| Q91029586 | Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling |
| Q91656347 | Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein |
| Q59799358 | Identification of Immune Signatures of Novel Adjuvant Formulations Using Machine Learning |
| Q92475802 | Identification of Plasmodium falciparum proteoforms from liver stage models |
| Q61446493 | Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02 |
| Q90461228 | Immunologic Dose-Response to Adenovirus-Vectored Vaccines in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral Vaccine Vectors when Given via an Intramuscular or Subcutaneous Route |
| Q62486713 | Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure |
| Q38735533 | Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. |
| Q56362064 | Malaria Vaccines: Recent Advances and New Horizons |
| Q90067337 | Malaria eradication within a generation: ambitious, achievable, and necessary |
| Q58569727 | Malaria prevention: from immunological concepts to effective vaccines and protective antibodies |
| Q96607419 | Malaria vaccines since 2000: progress, priorities, products |
| Q94602401 | Malaria vaccines: facing unknowns |
| Q55710825 | Modelling population-level impact to inform target product profiles for childhood malaria vaccines. |
| Q100517410 | Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination |
| Q90595442 | Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens |
| Q64935759 | Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites. |
| Q56342367 | Opportunities for Host-targeted Therapies for Malaria |
| Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
| Q89514056 | Plasmodium falciparum pre-erythrocytic stage vaccine development |
| Q56342409 | Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Circumsporozoite Protein Antigens |
| Q50029763 | RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype |
| Q90214251 | RTS,S/AS01 vaccine (Mosquirix™): an overview |
| Q36247474 | Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax |
| Q37696415 | Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes |
| Q57480738 | Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP |
| Q92449403 | Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ) |
| Q64091060 | SnoopLigase peptide-peptide conjugation enables modular vaccine assembly |
| Q47161602 | Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein |
| Q92802893 | T cell-mediated immunity to malaria |
| Q47977891 | The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination |
| Q55432397 | The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. |
| Q39170404 | Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection |
| Q100724843 | Understanding vaccine-elicited protective immunity against pre-erythrocytic stage malaria in endemic regions |
| Q58375482 | Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making |
| Q47134819 | malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication |